iCliniq Logo
HomeHealth articlesMedical oncologyhepatocellular carcinoma

Atezolizumab - Usage, Dosage, Side Effects, Drug Warnings, and Precautions

Verified data
0

5 min read

Share

Outline

Atezolizumab is a drug that helps the immune system fight small-cell lung cancer and liver cancer by helping the body recognize and attack cancer cells.

Medically reviewed byDr. Rajesh Gulati

Published At September 29, 2022
Reviewed AtFebruary 10, 2026

What Is Atezolizumab?

Atezolizumab is a medicine used to treat cancer. It is a type of drug called a monoclonal antibody. It works on a protein called PD-L1 (programmed death-ligand 1), which is found on cancer cells. Atezolizumab is approved by the FDA as a second treatment for urothelial cancer. It is waiting for approval for non-small cell lung cancer. Doctors also use this drug to treat melanoma, small-cell lung cancer, and liver cancer (hepatocellular carcinoma).

Whom to Give Atezolizumab?

Atezolizumab can be given alone or with other cancer medicines, such as Bevacizumab, Cobimetinib, Vemurafenib, Paclitaxel, and Carboplatin.

How Does Atezolizumab Work?

Cancer cells use a protein called PD-L1 to hide from the immune system. Atezolizumab attaches to this protein. This helps the immune system see and attack cancer cells. It slows down the growth of cancer.

Dosage and Forms

Atezolizumab comes as a single-dose vial. Available strengths are 840 mg in 14 mL and 1200 mg in 20 mL. Both contain 60 mg per mL.

Dosage for Different Cancers

1. Small Cell Lung Cancer:

1200 mg given through a vein on day 1. It is given every 2nd, 3rd, or 4th week. Treatment continues until the cancer worsens or side effects become serious.

2. Liver Cancer (Hepatocellular Carcinoma):

Atezolizumab 1200 mg with Bevacizumab 15 mg/kg. It is given through a vein on day 1. It is repeated every 3 weeks. It is continued until the disease worsens or side effects become severe.

How Is the Drug Given?

Atezolizumab is given through a vein (intravenously). The first dose takes 60 minutes. Later doses take 30 minutes if the first dose is well tolerated. It is given every 2nd, 3rd, or 4th week. It must not be given as a quick injection. Other drugs should not be given through the same IV line.

Uses of Atezolizumab

Atezolizumab is used to treat:

  • Extensive-stage small-cell lung cancer.
  • Advanced or spreading urothelial cancer.
  • Liver cancer (with Bevacizumab).
  • Melanoma (with Cobimetinib and Vemurafenib).
  • Metastatic non-small cell lung cancer (alone).
  • Metastatic non-squamous lung cancer with other chemotherapy drugs.

For Patients

Before Starting Atezolizumab

This drug can sometimes harm normal organs in the body. Some side effects can be serious or life-threatening. Problems can happen during or after treatment.

When and How Often Is It Given?

Atezolizumab is given through a vein for 30 to 60 minutes. It is given every 2nd, 3rd, or 4th week. Only a healthcare professional can give it. Treatment may last up to two years. Your doctor decides the total treatment time.

Tell Your Doctor Before Taking Atezolizumab If You:

  • Have had an organ transplant.
  • Have immune diseases like Crohn’s disease or lupus.
  • Have had or will have a stem cell transplant.
  • Have had radiation to the chest.
  • Are pregnant or planning a pregnancy.
  • Are breastfeeding or planning to breastfeed.
  • Take vitamins, herbal products, or other medicines.

After Starting Treatment

  • Keep all doctor appointments.
  • Do not miss doses.
  • Doctors will check for side effects.
  • Tests may be done to monitor your health.
  • Treatment may be stopped if side effects are severe.

Possible Side Effects

1. When Used Alone

  • Cough.
  • Nausea.
  • Loss of appetite.
  • Shortness of breath.
  • Tiredness.

2. When Used With Other Cancer Drugs

  • Nausea.
  • Diarrhea.
  • Hair loss.
  • Constipation.
  • Loss of appetite.
  • Tiredness.

3. In Liver Cancer

  • Tiredness.
  • High blood pressure.
  • Protein in urine.

4. In Triple-Negative Breast Cancer

  • Cough.
  • Headache.
  • Nausea and vomiting.
  • Diarrhea or constipation.
  • Low red blood cells.
  • Low white blood cells.
  • Hair loss.
  • Tingling or numbness in the hands and feet.

5. In Melanoma

  • Skin rash.
  • Itching.
  • Joint, muscle, or bone pain.
  • Liver injury.
  • Fever.
  • Swelling of hands, feet, or mouth.
  • Low thyroid hormone.
  • Sunburn.

Missed Dose

If you miss an appointment, contact your doctor immediately. Reschedule as soon as possible.

Regular visits are very important.

Overdose

Overdose is very rare. The drug is given only by healthcare professionals. If an overdose occurs, one should contact the emergency department.

Storage

Store in a refrigerator at 2°C to 8 °C (degrees Celsius). Keep in original packaging. Protect from light. Do not freeze or shake the vial. Patients cannot store or use it themselves. Used vials are safely destroyed by medical staff.

For Doctors

Pharmacology

Mechanism of Action:

Atezolizumab is a humanized immunoglobulin G antibody that binds to the PD-L1 (programmed death ligand 1) and inhibits its attachment to the PD-1 and B7.1 receptors. PD-L1-mediated immune response inhibition gets released, activating an anti-tumor immune response sans antibody-dependent cellular cytotoxicity. PD-L1 activity blockade decreased tumor growth in mouse tumor models, providing rather striking mechanistic insights.

Pharmacodynamics:

Atezolizumab boasts unusually prolonged efficacy and is administered roughly every 3 or 4 weeks, rather than on infrequent dosing schedules.

Ingredients

Active Ingredient:

The active ingredient in this medicine is Atezolizumab.

Inactive Ingredients:

The inactive ingredients are glacial acetic acid, L-histidine, sucrose, polysorbate 20, and pharmacokinetics.

Absorption

Studies were done in patients with urothelial cancer. The AUC value ranged from 2.19 to 2.73 micrograms/mL. The Cmax value ranged from 0.27 to 0.35 micrograms/mL. These numbers show how much of the drug stays in the body after dosing.

Distribution

The drug spreads in the body with a volume of 6.91 liters. This medicine does not attach to normal blood proteins. It attaches only to PD-L1 on cancer cells. This helps reduce tumor growth.

Metabolism

Atezolizumab breaks down into small proteins and amino acids. This happens naturally inside the body.

Elimination

The drug is not removed by the kidneys. It stays in the body for about five months while breaking down.

Warnings and Precautions

Immune-Mediated Side Effects

This drug can cause the immune system to attack normal organs.

It can affect:

  • Lungs (pneumonitis).
  • Intestines (colitis).
  • Liver (hepatitis).
  • Hormone glands
  • Skin.
  • Kidneys.
  • Transplanted organs.

Other serious immune reactions may affect:

  • Heart.
  • Blood vessels.
  • Eyes.
  • Brain and nerves.
  • Pancreas.
  • Muscles.
  • Blood cells.
  • Lymph nodes.

Doctors must monitor all organs closely. The drug may be stopped if reactions are severe.

Infusion-Related Reactions

Some patients may react during the infusion. The infusion may be slowed, stopped, or ended. This depends on how serious the reaction is.

Stem Cell Transplant Complications

Serious problems can occur if patients receive stem cell transplants. This can happen before or after Atezolizumab treatment. Possible problems include graft-versus-host disease and liver blood vessel disease. These patients must be monitored very carefully. Treatment should be stopped immediately if problems appear.

Pregnancy and Fetal Risk

Atezolizumab can harm an unborn baby. There are no studies in pregnant women. Animal studies show the immune system may reject the fetus. Women must be checked for pregnancy before treatment and use birth control during treatment.

Contraindications of Atezolizumab:

  • Active infection.
  • Low thyroid hormone.
  • Overactive thyroid.
  • Type 1 diabetes.
  • Myasthenia gravis.
  • Lung inflammation.
  • Large intestine inflammation
  • Adrenal gland problems.
  • Liver inflammation.
  • Muscle inflammation.
  • Kidney inflammation.
  • Pancreatitis
  • Pituitary gland inflammation
  • Pregnancy.
  • Breastfeeding.

Drug Interactions

Atezolizumab can interact with other medicines. Drugs that reduce its effect include immunosuppressants and corticosteroids.

Use in Special Groups

  1. Pregnancy:

The drug can cause fetal death. It should not be used during pregnancy.

  1. Breastfeeding:

It is unknown if the drug enters breast milk. Do not breastfeed during treatment.

  1. Children:

Safety in children is not fully known. No new safety problems have been reported so far.

  1. Older Adults:

No major safety differences were seen in older patients.

  1. Kidney Disease:

No dose change is needed for mild to moderate kidney disease. There is no data for severe kidney failure.

  1. Liver Disease:

The drug is not recommended in severe liver disease. No dose change is needed for mild liver problems.

Conclusion

Atezolizumab is an advanced cancer medicine. It helps the immune system fight cancer. It is effective in lung cancer, liver cancer, and melanoma. However, it can cause serious immune side effects. Careful monitoring by doctors is very important. Talk to a cancer specialist for proper evaluation.

Key Takeaways

  • Atezolizumab helps in the treatment of different kinds of cancer.
  • It is given under medical supervision in the form of an injection.
  • It is not advised during pregnancy or breastfeeding.
  • It is recommended to visit a doctor in case of any side effects.
Listen to related tracks in our music library

Frequently Asked Questions

Atezolizumab treats cancers such as bladder, liver, lung cancer, and melanoma. It is often used with chemotherapy for certain types of small-cell lung cancer, hepatocellular carcinoma, and melanoma in adults.

Atezolizumab blocks the protein, which stops the immune system from working properly and attacks the cancer cells. It helps to find the immune system, kills the cancer cells, and also slows down tumor growth.
Platinum-based chemotherapy is not eligible in individuals with advanced non-small cell lung cancer; Atezolizumab is proven to improve overall survival and has fewer adverse events when compared to single-agent chemotherapy.

The most common side effects are neck, arm, back, or leg pain, change or loss in taste, hair loss or thinning of hair, moving difficulties, unsteadiness or weakness, weakness in hands, arms, legs, or feet.

The dosage of Atezolizumab is 1200 mg, given through intravenous infusion every three weeks over 60 minutes until the disease progresses or there is unacceptable toxicity. If the infusion given first is tolerated, all subsequent infusions can be delivered over 30 minutes.
The dosage form of Atezolizumab is 1200 mg/20mL given through intravenous infusion colorless to slightly yellow solution in a single-dose vial.
Atezolizumab can cause liver test abnormalities and immune-mediated hepatitis. Fatal cases have been reported. Therefore, signs and symptoms of hepatitis should be monitored in patients during and even after the discontinuation of Atezolizumab.

Atezolizumab is an immunotherapy drug used to treat bladder, liver, lung cancer, and melanoma. It boosts the immune system and may be used alone or with chemotherapy in adults.

Immunotherapy should be stopped after two years in order to reduce the side effects and improve the quality of life, and also to reduce financial issues and physical toxicities related to it.

Atezolizumab can cause immune-mediated adverse reactions such as immune-mediated pneumonitis, immune-mediated hepatitis, immune-mediated colitis, and immune-mediated endocrinopathies.

 
Atezolizumab can cause common side effects such as hair loss when used with other anticancer treatments in patients being treated for advanced lung cancer. It can also lead to problems related to hormone glands, which can further cause hair loss.
 
The cycle length is twenty-one days. The duration of therapy is four cycles plus maintenance of Atezolizumab monotherapy. 
 
Atezolizumab is considered a hazardous drug as it can cause embryo-fetal toxicity and may also impair fertility in females of reproductive potential. This drug only in non-cytotoxic drugs is marked as developmental and/or reproductive hazardous.

Atezolizumab is made from glacial acetic acid, histidine, sucrose, and polysorbate.

Atezolizumab was approved by the FDA on December 9th, 2022, for adult and pediatric patients aged 2 years and above with unresectable or metastatic alveolar soft part sarcoma. The brand name of this drug is Tecentriq, which is approved by the FDA.

Source Article IclonSourcesSource Article Arrow

Tags:

hepatocellular carcinomasmall cell lung canceratezolizumab

Ask your health query to a doctor online

Medical oncology

*guaranteed answer within 4 hours

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.